By 2026, Italy will introduce an adrenaline nasal spray to treat severe anaphylactic reactions, offering a needle-free alternative to traditional injections.
Already approved by the FDA and EMA in 2024 and available in Germany, the spray marks a major step forward in managing life-threatening allergic reactions.
“Allergies are the most common chronic condition in Europe, affecting around 150 million people, with 10,000 cases of anaphylaxis every year in Italy alone,” explains Vincenzo Patella, president of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).
Easy to use even without medical assistance, the nasal spray could enable faster response times in emergencies, complementing existing autoinjectors and potentially saving lives.
|